MarketPulse

PALISADE-3 study

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Vistagen Faces Securities Fraud Lawsuit Over Failed Phase 3 Trial Results

Vistagen faces class action lawsuit for securities fraud after its Phase 3 trial failed, causing stock to plummet 80%. Investors allege misleading statements about trial progress.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Launches Class Action Against Vistagen Following Failed Trial, Sets March Deadline

Pomerantz launches class action against Vistagen after failed clinical trial caused 80% stock drop. March 16, 2026 deadline for investors to join lawsuit.
SDMVTGNCLEUFsecurities fraudclass action lawsuit